Yaşlilikta Tedavi Kilavuzu indb

YAŞLILIKTA DİSLİPİDEMİ
11.  Savarese G, Gotto AM Jr, Paolillo S, D’Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, 
De Luca G, Trimarco B, Perrone-Filardi P Benefits of statins in elderly subjects without established cardiovascular 
disease: a meta-analysis.J Am Coll Cardiol. 2013 Dec;62(22):2090-9. Epub 2013 Aug 28.
12.  Hamilton-Craig I1, Colquhoun D2, Kostner K3, Woodhouse S4, d’Emden M5.Lipid-modifying therapy in the 
elderly.Vasc Health Risk Manag. 2015 May 14;11:251-63. doi: 10.2147/VHRM.S40474. eCollection 2015.
13.  Corti MC, Guralnik JM, Salive ME, Harris T, Ferrucci L, Glynn RJ, Havlik RJ Clarifying the direct relation between 
total cholesterol levels and death from coronary heart disease in older persons.Ann Intern Med. 1997;126(10):753.
14.  Hamilton-Craig I, Michealides C, Kostner K, Van Bockxmeer F. Current initiatives for detecting patients with 
familial hypercholesterolemia in primary care. Lipid Spin. 2013;11:5–10.
15.  Pate R, Pratt M, Blair S, et al. Physical activity and public health. A recommendation from the Centers for Disease 
Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273: 402–407.
16.  Pate R, Pratt M, Blair S, et al. Physical activity and public health. A recommendation from the Centers for Disease 
Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273: 402–407.
17.  Lavie CJ. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy and drug 
combination. Am J Geriatr Cardiol 2004; 13 (3, Suppl. 1):29–33.
18.  Garcia-Palmiery M. Control of blood lipids in the elderly. Bol Asoc Med PR 2003; 95: 84–90.
19.  Pedersen TR. Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol 1998; 
82: 53T–56T.
20.  Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in 
patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 
335: 1001–1009.
21.  The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovas-
cular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol 
levels. N Engl J Med 1998; 339: 1349–1357.
22.   Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and 
women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosisi 
Prevention Study. JAMA 1998; 279: 1615–1622.
23.  Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a 
randomised controlled trial. PROSPER study group. Prospective Study of Pravastatin in the Elderly at Risk. Lancet 
2002; 360: 1623–1630.
24.   Heart Protection Study Collaborative Group. MRC/BHF heart Protection Study of antioxidant vitamin supple-
mentation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23–33.
25.  Sever PS, Dahlof B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvas-
tatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo–Scan-
dinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. 
Lancet 2003; 361: 1129–1158.
26.  Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol 2002; 11: 101–107.
27. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease. Circulation. 
2007;115:450–458.
28.  Lipka L, Sager P, Strony J, et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients 
with primary hypercholesterolaemia. Drugs Aging. 2004;21(15): 1025–1032.
29.  Scaldaferri F, Pizzoferrato M, Ponziani FR, Gasbarrini G, Gasbarrini A. Use and indications of cholestyramine and 
bile acid sequestrants. Intern Emerg Med. 2013;8(3):205-10.
30.  Authors/Task Force Members:., Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes 
AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren 
WM, Vlachopoulos C, Wood DA, Zamorano JL.Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosc-
lerosis.2016.08.018.2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the 
Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society 
(EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & 
Rehabilitation (EACPR).

---

---

Bölüm